Related Experiment Video
Updated: Oct 1, 2026

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy
Published on: August 9, 2024
[Therapy of infantile spasms (West syndrome) with sodium dipropylacetate]
Insights
Sodium Dipropylacetic acid (DPK) effectively reduced infantile spasms in 40% of idiopathic cases and 11% of secondary cases. Long-term follow-up showed persistent seizures in some patients, with mental retardation noted in both groups.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Context:
- Infantile spasms syndrome (ISS) is a severe epilepsy syndrome in infants.
- Treatment options for ISS include anticonvulsants and hormonal therapy.
Purpose:
- To evaluate the efficacy and long-term outcomes of Sodium Dipropylacetic acid (DPK) in treating infantile spasms.
- To compare treatment responses based on etiology (idiopathic vs. secondary ISS).
Summary:
- 42 patients with infantile spasms were treated with DPK, divided into idiopathic and secondary groups.
- DPK showed varying efficacy: 40% seizure-free in idiopathic, 11.1% in secondary. Long-term follow-up revealed persistent seizures in 18.18% (idiopathic) and 28.57% (secondary).
- Mental retardation was observed in 36.36% of idiopathic and 57.14% of secondary cases.
Impact:
- DPK demonstrates significant efficacy in managing infantile spasms, particularly in idiopathic cases.
- The study highlights the importance of considering etiology for treatment strategies in infantile spasms.
- Findings support the use of anticonvulsants as a first-line treatment for ISS, with hormonal therapy (ACTH) reserved for refractory cases.
Abstract:
The authors report the results obtained in 42 patients affected by infantile spasms syndrome during treatment with Sodium Dipropylacetic acid. The subjects were divided into two groups according to the aetiology: idiopathic and secondary. In the first group the use of DPK as determined the disappearance of the seizures in 6 cases (40%), reduction of the crises beyond 50% in 7 cases (46.6%), while in 2 subjects (13.3%) the crises persisted. In the secondary group the crises ceased in 3 cases (11.1%), in 17 (62.9%) there were a reduction of the crises beyond 50%, no response to the drug was observed in 7 subjects (25.9%). In 10 patients the anticonvulsant treatment was progressively diminished and was substituted with hormonal treatment. The long term follow up (1-6 years) gives the following results: the seizures persisted in 2 cases (18.18%) among the idiopathic form and in 6 cases (28.57%) among the secondary group. Mental retardation was found in 4 subjects (36.36%) among the idiopathic group and in 12 patients (57.14%) among the secondary group. The authors shortly report the side effect of the hormonal treatment: they prefer the initiation of treatment of I.S. with anticonvulsant drug and suggest to resort to the ACTH when the initial treatment is unsuccessful.
Related Concept Videos
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Tetanus

